Search in:

Advanced search

Journal of Medical Economics Volume 27, 2024 - Issue 1

Submit an article Journal homepage

Open access

400

Views

CrossRef citations to date

Altmetric

Neurology

Quantifying preferences for urea cycle disorder treatments using a discrete choice experiment

Josiah Edelbluta Trinity Life Sciences, Waltham, MA, USAView further author information

Jeffrey R. Skaara Trinity Life Sciences, Waltham, MA, USAView further author information

John Hiltonb Acer Therapeutics, Newton, MA, USA, a wholly owned subsidiary of Zevra TherapeuticsView further author information

Matthew Seibtb Acer Therapeutics, Newton, MA, USA, a wholly owned subsidiary of Zevra TherapeuticsView further author information

Kyle Martina Trinity Life Sciences, Waltham, MA, USAView further author information

Nandini Hadkera Trinity Life Sciences, Waltham, MA, USAView further author information

Adrian Quartelb Acer Therapeutics, Newton, MA, USA, a wholly owned subsidiary of Zevra TherapeuticsView further author information

Robert D. Steinerc Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USACorrespondence[email protected]

https://orcid.org/0000-0003-4177-4590 View further author information

show all

Pages 506-517 | Received 23 Jan 2024, Accepted 12 Mar 2024, Published online: 31 Mar 2024

Cite this article
https://doi.org/10.1080/13696998.2024.2330846
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

Summar ML, Mew NA. Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders. Pediatr Clin North Am. 2018;65(2):231–246. doi:10.1016/j.pcl.2017.11.004.
PubMed Web of Science ®Google Scholar
Batshaw ML, Tuchman M, Summar M, et al. A longitudinal study of urea cycle disorders. Mol Genet Metab. 2014;113(1–2):127–130. doi:10.1016/j.ymgme.2014.08.001.
PubMed Web of Science ®Google Scholar
Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab. 2013;110(1–2):179–180. doi:10.1016/j.ymgme.2013.07.008.
PubMed Web of Science ®Google Scholar
Enns GM, Porter MH, Francis-Sedlak M, et al. Perspectives on urea cycle disorder management: results of a clinician survey. Mol Genet Metab. 2019;128(1–2):102–108. doi:10.1016/j.ymgme.2019.07.009.
PubMed Web of Science ®Google Scholar
Häberle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7(1):32. doi:10.1186/1750-1172-7-32.
PubMedGoogle Scholar
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192–1230. doi:10.1002/jimd.12100.
PubMed Web of Science ®Google Scholar
Peña-Quintana L, Llarena M, Reyes-Suárez D, et al. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives. Patient Prefer Adherence. 2017;11:1489–1496. doi:10.2147/PPA.S136754.
PubMed Web of Science ®Google Scholar
Ficicioglu C, Liu N, Sun Q, et al. Perceptions and use of phenylbutyrate metabolite testing in urea cycle disorders: results of a clinician survey and analysis of a centralized testing database. Mol Genet Metab. 2022;135(1):35–41. doi:10.1016/j.ymgme.2021.12.007.
PubMed Web of Science ®Google Scholar
RAVICTI Prescribing Informatoin. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203284s012lbl.pdf: US FDA; 2023. [cited 2023 January 12, 2023]; RAVICTI Prescribing Information]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203284s012lbl.pdf.
Google Scholar
BUPHENYL Prescribing Information: US FDA. 2023. [cited 2023 January 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020572s016,020573s015lbl.pdf.
Google Scholar
Shchelochkov OA, Dickinson K, Scharschmidt BF, et al. Barriers to drug adherence in the treatment of urea cycle disorders: assessment of patient, caregiver and provider perspectives. Mol Genet Metab Rep. 2016;8:43–47. doi:10.1016/j.ymgmr.2016.07.003.
PubMed Web of Science ®Google Scholar
Yeowell G, Burns DS, Fatoye F. The burden of pharmacological treatment on health-related quality of life in people with a urea cycle disorder: a qualitative study. J Patient Rep Outcomes. 2021;5(1):110. doi:10.1186/s41687-021-00387-x.
PubMedGoogle Scholar
Summar ML, Dobbelaere D, Brusilow S, et al. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97(10):1420–1425. doi:10.1111/j.1651-2227.2008.00952.x.
PubMed Web of Science ®Google Scholar
Ryan M. Discrete choice experiments in health care. BMJ. 2004;328(7436):360–361. doi:10.1136/bmj.328.7436.360.
PubMed Web of Science ®Google Scholar
Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19(4):300–315. doi:10.1016/j.jval.2016.04.004.
PubMed Web of Science ®Google Scholar
Conn VS, Ruppar TM, Chan KC, et al. Packaging interventions to increase medication adherence: systematic review and meta-analysis. Curr Med Res Opin. 2015;31(1):145–160. doi:10.1185/03007995.2014.978939.
PubMed Web of Science ®Google Scholar
Gutierrez PM, Wortzel HS, Forster JE, et al. Blister packaging medication increases treatment adherence in psychiatric patients. J Psychiatr Pract. 2017;23(5):320–327. doi:10.1097/PRA.0000000000000252.
PubMed Web of Science ®Google Scholar
Shah G, Erickson JL, Luxenburg J, et al. Impact on patients’ compliance with medication using prepacked blisters for multidrug medical therapy: I-COMPLY study. Am J Health Syst Pharm. 2021;78(18):1713–1719. doi:10.1093/ajhp/zxab193.
PubMed Web of Science ®Google Scholar
Yeboah-Antwi K, Gyapong JO, Asare IK, et al. Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment. Bull World Health Organ. 2001;79(5):394–399.
PubMed Web of Science ®Google Scholar
Waisbren SE, Stefanatos AK, Kok TMY, et al. Neuropsychological attributes of urea cycle disorders: a systematic review of the literature. J Inherit Metab Dis. 2019;42(6):1176–1191. doi:10.1002/jimd.12146.
PubMed Web of Science ®Google Scholar
Drug Removals for Clients with Advanced Control Specialty Formulary: CVS Caremark. 2023. [cited 2023 January 12]. Available from: https://www.caremark.com/portal/asset/Formulary_Drug_Removals_JPMC.pdf.
Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Quantifying preferences for urea cycle disorder treatments using a discrete choice experiment

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Quantifying preferences for urea cycle disorder treatments using a discrete choice experiment

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date